Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adicet Bio (ACET) has issued an update.
Adicet Bio, Inc. has announced that their innovative therapy, ADI-001, has been granted Fast Track Designation by the FDA for the treatment of Lupus Nephritis. This significant development could potentially accelerate the approval process and bring this new treatment to patients sooner, signaling a promising advancement in the fight against this challenging autoimmune disease.
For an in-depth examination of ACET stock, go to TipRanks’ Stock Analysis page.